



Sociedad Española  
de Reumatología -  
Colegio Mexicano  
de Reumatología

# Reumatología Clínica

www.reumatologiaclinica.org



## Editorial

### Vitamin D and cardiovascular disease in patients with systemic lupus erythematosus<sup>☆</sup>



### Vitamina D y enfermedades cardiovasculares en pacientes con lupus eritematoso sistémico

Mario García-Carrasco,<sup>a,b,\*</sup> Jose Luis Romero-Galvez<sup>c</sup>

<sup>a</sup> Departamento de Inmunología y Reumatología, Facultad de Medicina, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico

<sup>b</sup> Unidad de Investigación de Enfermedad Autoinmunes Sistémicas, Hospital General Regional #36, Instituto Mexicano del Seguro Social, Puebla, Mexico

<sup>c</sup> Servicio de Alergología e Inmunología, Hospital Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Puebla, Mexico

Systemic lupus erythematosus (SLE) is an autoimmune disease of unknown etiology, in which genetic, environmental and immunological factors participate. It can affect joints, kidneys, skin, nervous system and cardiovascular system. The patients present a high risk of development of early cardiovascular disease, with atherosclerosis being the most frequent cardiac disease.<sup>1–3</sup> Manifestations like myocarditis, valve diseases, thrombosis, vasculitis and accelerated atherosclerosis have been identified.<sup>4</sup> In fact, we have reported that a large percentage of patients with SLE have structural or functional heart disease.<sup>5</sup> Cardiovascular risk factors have been extensively studied in SLE patients, in whom hypertension, dyslipidemia, tobacco use and diabetes mellitus do not explain the accelerated cardiovascular disease.<sup>1,5</sup> Therefore, it is important to considerate the so-called nontraditional factors or those related to the disease: disease duration, age at diagnosis, disease activity, corticosteroid doses and presence of antiphospholipid antibodies.<sup>1,6</sup> Among the unclassical risk factors for the development of atherosclerosis, vitamin D deficiency has been proposed in patients with SLE,<sup>7,8</sup> although a number of studies do not show this association.<sup>9,10</sup>

Vitamin D is a hormone with an immunoregulatory role that induces improvement in phagocytosis and reduces major histocompatibility complex class II DR in dendritic cells, while it induces maturity in natural killer cells and CD4<sup>+</sup>CD25<sup>+</sup>FOXP3 T cells, with the ability to mediate immune tolerance, reducing the development of autoimmune disorders.<sup>11</sup> These findings support different studies *in vitro*, in which the low serum vitamin D concentrations were related to the decrease in the expression of T helper (Th) 17 and Th1 proinflammatory cytokines and the increase in that of Th2 and T regulatory cytokines.<sup>12–14</sup> Some of these studies suggest that vitamin D supplementation could prevent endothelial damage produced by neutrophil extracellular traps,<sup>15</sup> in which

there is a decrease in interferon  $\alpha$  (IFN $\alpha$ ) and inhibition of antigen-presenting cells.<sup>16,17</sup> Moreover, this vitamin can reduce interleukin (IL) 6 and IL-10 messenger RNA expression and increase that of transforming growth factor (TGF)- $\beta$ 3 and the percentage of T regulatory cells.<sup>18</sup> It has also been observed that vitamin D supplementation decreases the expression of Th1, Th17 and B cells, with reduction in the production of anti-DNA autoantibodies.<sup>19,20</sup>

There is controversy as to whether vitamin D deficiency actually contributes to the atherosclerosis in SLE patients, and if supplements with that vitamin can reduce cardiovascular risk in these patients. Our group has reported that patients with SLE have a high vitamin D insufficiency and deficiency with respect to the healthy population.<sup>21</sup> The deficiency of vitamin D is related to the absence of exposure to sunlight and the use of sunscreens as part of the treatment of photosensitivity of the patients with this disease, as is the history of chronic kidney disease and the use of chronic corticosteroids, anticonvulsants and antimalarial agents,<sup>8,9</sup> with lupus nephritis<sup>22</sup> and accumulated doses of corticosteroids<sup>23,24</sup> the most important factors.

The disease activity in SLE patients and its possible relationships with serum vitamin D level has also been controversial. Chen et al. demonstrated that vitamin D supplementation can modulate the production of proinflammatory cytokines and reduce the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score,<sup>20</sup> with each relationship between vitamin D and disease activity having been corroborated by other studies.<sup>12,25,26</sup> On the other hand, Sahebari et al. did not observe this corroboration.<sup>23</sup>

The administration of vitamin D supplementation can be useful in those individuals with cardiovascular risk factors, due to the fact that there is a possible association of the vitamin D deficiency and subclinical atherosclerosis.<sup>27</sup> The deficiency of this vitamin has been related to hyperlipidemia, insulin resistance, blood flow disturbances and arterial stiffness.<sup>28,29</sup> In SLE patients, there is a relationship of cardiovascular involvement with risk factors such as severe disease activity, collateral effects of immunosuppressant agents and obesity.<sup>30</sup> Moreover, diverse studies demonstrate that vitamin D deficiency is related to a greater expression of metabolic disorders and insulin resistance, but not to subclinical atherosclerosis or cardiovascular involvement in patients with SLE.<sup>31,32</sup>

<sup>☆</sup> Please cite this article as: García-Carrasco M, Romero-Galvez JL. Vitamina D y enfermedades cardiovasculares en pacientes con lupus eritematoso sistémico. Reumatol Clin. 2016;12:241–243.

\* Corresponding author.

E-mail address: [mgc30591@yahoo.com](mailto:mgc30591@yahoo.com) (M. García-Carrasco).

With relationship to vitamin D supplements, concentrations of 4000 IU daily or 25,000 IU monthly do not reduce proinflammatory cytokines as does interferon  $\gamma$ ,<sup>33</sup> disease activity or cardiovascular involvement in SLE patients. Other studies demonstrating that 300,000 IU in a bolus followed by 50,000 IU administered monthly during 1 year did not show marked modifications in disease activity.<sup>34,35</sup> However, these doses have an adequate safety margin, and achieve increases in T regulatory cells and decreases in the proinflammatory Th1 and Th17 immune responses.<sup>36</sup> Abou-Raya et al. demonstrated that patients with SLE and vitamin D deficiency had a decrease in proinflammatory cytokines and an increase in the hemostatic markers following supplementation.<sup>37</sup>

Although the doses and duration of vitamin D administration are not known, sustained doses to achieve a concentration of 32 ng/mL can improve the vascular blood flow and reduce apoptosis of the vascular<sup>38</sup> endothelium and neutrophil activity in SLE patients.<sup>15</sup> Lertratanakul et al. found a relationship between vitamin D deficiency with hypertension, hyperlipidemia and an increase in C-reactive protein; however, in this deficiency, they did not find an independent factor in the incidence of cardiovascular events. On the other hand, they did find an association between the serum vitamin D levels, with greater cardiovascular risk when analyzed with the successive concentration in the groups with greater serum vitamin D levels and, thus, with greater concentration when the cardiovascular risk was lesser.<sup>39</sup> Skaaby observed a relative risk of 0.95 for each 10 nmol/L higher in the vitamin D level for a decrease in triglycerides, hyperlipidemia and metabolic syndrome, but there was no relationship to the incidence of myocardial infarction or stroke.<sup>40</sup> Given the evidence of the association of vitamin D with cardiovascular risk in SLE patients, we can conclude a series of important points: (1) It is probable that vitamin D deficiency in patients with SLE is related to a greater disease activity; (2) The cardiovascular complications of SLE patients are related to the serious of the disease activity, the collateral effects of immunosuppressant agents and the standard cardiovascular risk factors; (3) The vitamin D deficiency in SLE patients seems to have more to do with metabolic disorders than with cardiovascular disease *per se*; (4) Maintaining optimal serum vitamin D levels in SLE patients would probably be a protector of cardiovascular risk; and (5) At the present time, it is reasonable to give supplemented vitamin D doses to any patient with deficiency of this vitamin and/or standard cardiovascular risk factors.

## References

1. Frostegard J. Prediction and management of cardiovascular outcomes in systemic lupus erythematosus. *Expert Rev Clin Immunol.* 2015;11:247–53.
2. Schoenfeld SR, Kasturi S, Costenbader KH. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. *Semin Arthritis Rheum.* 2013;43:77–95.
3. Escárcega RO, García-Carrasco M, Jara LJ, Cervera R. Accelerated atherosclerosis in systemic lupus erythematosus: perspectives towards decreasing cardiovascular morbidity and mortality. *Lupus.* 2009;18:383–6.
4. Fessler BJ, Boumpas DT. Severe major organ involvement in systemic lupus erythematosus. Diagnosis and management. *Rheum Dis Clin North Am.* 1995;21:81–98.
5. García-Carrasco M, Escárcega RO, Pérez-Terrón J, Ramírez A, Muñoz-Guarneros M, Beltrán A, et al. Lack of subclinical myocardial ischaemia in Mexican patients with systemic lupus erythematosus without traditional risk factors for coronary artery disease. *Lupus.* 2007;4:298–301.
6. Reynolds JA, Haque S, Berry JL, Pemberton P, Teh LS, Ho P, et al. 25-Hydroxyvitamin D deficiency is associated with increased aortic stiffness in patients with systemic lupus erythematosus. *Rheumatology (Oxford).* 2012;51:544–51.
7. Cheraghi N, Dai H, Raghuvveer G. Vitamin D deficiency is associated with atherosclerosis-promoting risk factor clustering but not vascular damage in children. *Med Sci Monit.* 2012;18:687–92.
8. Reis JP, von Muhlen D, Michos ED, Miller ER, Appel LJ, Araneta MR, et al. Serum vitamin D, parathyroid hormone levels, and carotid atherosclerosis. *Atherosclerosis.* 2009;207:585–90.
9. Mok CC, Birmingham DJ, Leung HW, Hebert LA, Song H, Rovin BH, et al. Levels in Chinese patients with systemic lupus erythematosus: relationship with

disease activity, vascular risk factors and atherosclerosis. *Rheumatology (Oxford).* 2012;51:644–52.

10. Sachs MC, Brunzell JD, Cleary PA, Hoofnagle AN, Lachin JM, Molitch ME, et al. Circulating vitamin D metabolites and subclinical atherosclerosis in type 1 diabetes. *Diabetes Care.* 2013;36:2423–9.
11. García-Carrasco M, Romero JL. Vitamin D and autoimmune rheumatic disease. *Reumatol Clin.* 2015;11:333–4.
12. Gatenby P, Lucas R, Swaminathan A. Vitamin D deficiency and risk for rheumatic diseases: an update. *Curr Opin Rheumatol.* 2013;25:184–91.
13. Handono K, Marisa D, Kalim H. Association between the low levels of vitamin D and Treg function in systemic lupus erythematosus patients. *Acta Med Indones.* 2013;45:26–31.
14. vinh quoc Luong K, Nguyen LT. The beneficial role of vitamin D in systemic lupus erythematosus (SLE). *Clin Rheumatol.* 2012;31:1423–35.
15. Handono K, Sidarta YO, Pradana BA, Nugroho RA, Hartono IA, Kalim H, et al. Vitamin D prevents endothelial damage induced by increased neutrophil extracellular traps formation in patients with systemic lupus erythematosus. *Acta Med Indones.* 2014;46:189–98.
16. Lerman M, Burnham J, Behrens E. 1,25 Dihydroxyvitamin D3 limits monocyte maturation in lupus sera. *Lupus.* 2011;20:749–53.
17. Ben-Zvi I, Aranow C, Mackay M, Stanevsky A, Kamen DL, Marinescu LM, et al. The impact of vitamin D on dendritic cell function in patients with systemic lupus erythematosus. *PLoS ONE.* 2010;5:e9193.
18. Lavi Arab F, Rastin M, Faraji F, Zamani Taghizadeh Rabe S, Tabasi N, Khazaei M, et al. Assessment of 1,25-dihydroxyvitamin D3 effects on Treg cells in a mouse model of systemic lupus erythematosus. *Immunopharmacol Immunotoxicol.* 2015;37:12–8.
19. Terrier B, Derian N, Schoindre Y, Chaara W, Geri G, Zahr N, et al. Restoration of regulatory and effector T cell balance and B cell homeostasis in systemic lupus erythematosus patients through vitamin D supplementation. *Arthritis Res Ther.* 2012;14:R221.
20. Chen S, Sims GP, Chen XX, Gu YY, Chen S, Lipsky PE. Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. *J Immunol.* 2007;179:1634–47.
21. García-Carrasco M, Mendoza-Pinto C, Etchegaray-Morales I, Soto-Santillán P, Jiménez-Herrera EA, Robles-Sánchez V, et al. Vitamin D Insufficiency and deficiency in Mexican patients with systemic lupus erythematosus: prevalence and relationship with disease activity. *Reumatol Clin.* 2016. <http://dx.doi.org/10.1016/j.reuma.2016.02.013>. S1699-258X(16)00046-2.
22. Sumethkul K, Boonyaratavej S, Kitumnuaypong T, Angthararuk S, Cheewasat P, Manadee N, et al. The predictive factors of low serum 25-hydroxyvitamin D and vitamin D deficiency in patients with systemic lupus erythematosus. *Rheumatol Int.* 2013;33:1461–7.
23. Sahebari M, Nabavi N, Salehi M. Correlation between serum 25(OH)D values and lupus disease activity: an original article and a systematic review with meta-analysis focusing on serum VitD confounders. *Lupus.* 2014;23:1164–77.
24. Chaiamnuay S, Chailurkit LO, Narongroeknawin P, Asavatanabodee P, Laohajaroensombat S, Chaiamnuay P. Current daily glucocorticoid use and serum creatinine levels are associated with lower 25(OH) vitamin D levels in Thai patients with systemic lupus erythematosus. *J Clin Rheumatol.* 2013;19:121–5.
25. Mandal M, Tripathy R, Panda AK, Pattanaik SS, Dakua S, Pradhan AK, et al. Vitamin D levels in Indian systemic lupus erythematosus patients: association with disease activity index and interferon alpha. *Arthritis Res Ther.* 2014;16:R49.
26. Sakthiswary R, Raymond AA. The clinical significance of vitamin D in systemic lupus erythematosus: a systematic review. *PLoS ONE.* 2013;8:e55275.
27. Ravenell RL, Kamen DL, Spence JD, Hollis BW, Fleury TJ, Janech MG, et al. Premature atherosclerosis is associated with hypovitaminosis D and angiotensin-converting enzyme inhibitor non-use in lupus patients. *Am J Med Sci.* 2012;344:268–73.
28. Sabio JM, Vargas-Hitos JA, Martínez-Bordonado J, Navarrete-Navarrete N, Díaz-Chamorro A, Olvera-Porcel C, et al. Association between low 25-hydroxyvitamin D, insulin resistance and arterial stiffness in nondiabetic women with systemic lupus erythematosus. *Lupus.* 2015;24:155–63.
29. Reynolds JA, Haque S, Berry JL, Pemberton P, Teh LS, Ho P, et al. 25-Hydroxyvitamin D deficiency is associated with increased aortic stiffness in patients with systemic lupus erythematosus. *Rheumatology (Oxford).* 2012;51:544–51.
30. Wu PW, Rhew EY, Dyer AR, Dunlop DD, Langman CB, Price H, et al. 25-hydroxyvitamin D and cardiovascular risk factors in women with systemic lupus erythematosus. *Arthritis Rheum.* 2009;61:1387–95.
31. Jung JY, Koh BR, Bae CB, Kim HA, Suh CH. Carotid subclinical atherosclerosis is associated with disease activity but not vitamin D in Korean systemic lupus erythematosus. *Lupus.* 2014;23:1517–22.
32. Kiani AN, Fang H, Magder LS, Petri M. Vitamin D deficiency does not predict progression of coronary artery calcium, carotid intima-media thickness or high-sensitivity C-reactive protein in systemic lupus erythematosus. *Rheumatology (Oxford).* 2013;52:2071–6.
33. Aranow C, Kamen DL, Dall'Era M, Massarotti EM, Mackay MC, Koumpouras F, et al. Randomized, double-blind, placebo-controlled trial of the effect of vitamin D3 on the interferon signature in patients with systemic lupus erythematosus. *Arthritis Rheumatol.* 2015;67:1848–57.
34. Andreoli L, Dall'Ara F, Piantoni S, Zanola A, Piva N, Cutolo M, et al. A 24-month prospective study on the efficacy and safety of two different monthly regimens of vitamin D supplementation in pre-menopausal women with systemic lupus erythematosus. *Lupus.* 2015;24:499–506.

35. Peracchi OA, Terreri MT, Munekata RV, Len CA, Sarni RO, Lazaretti-Castro M, et al. Low serum concentrations of 25-hydroxyvitamin D in children and adolescents with systemic lupus erythematosus. *Braz J Med Biol Res.* 2014;47:721–6.
36. Piantoni S, Andreoli L, Scarsi M, Zanola A, Dall'Ara F, Pizzorni C, et al. Phenotype modifications of T-cells and their shift toward a Th2 response in patients with systemic lupus erythematosus supplemented with different monthly regimens of vitamin D. *Lupus.* 2015;24:490–8.
37. Abou-Raya A, Abou-Raya S, Helmii M. The effect of vitamin D supplementation on inflammatory and hemostatic markers and disease activity in patients with systemic lupus erythematosus: a randomized placebo-controlled trial. *J Rheumatol.* 2013;40:265–72.
38. Kamen DL, Oates JC. A pilot study to determine if vitamin D repletion improves endothelial function in lupus patients. *Am J Med Sci.* 2015;350:302–7.
39. Lertratanakul A, Wu P, Dyer A, Urowitz M, Gladman D, Fortin P, et al. 25-Hydroxyvitamin D and cardiovascular disease in patients with systemic lupus erythematosus: data from a large international inception cohort. *Arthritis Care Res (Hoboken).* 2014;66:1167–76.
40. Skaaby T. The relationship of vitamin D status to risk of cardiovascular disease and mortality. *Dan Med J.* 2015;62.